Semax

What Is Semax?

Semax is a synthetic heptapeptide analogue of adrenocorticotropic hormone (ACTH 4-10), developed in Russia in the 1980s–90s by the Institute of Molecular Genetics of the Russian Academy of Sciences. It was originally created as a neuroprotective agent for stroke and traumatic brain injury, and has been approved in Russia and Ukraine since the late 1990s as a prescription medication for neurological conditions including cerebrovascular insufficiency, cognitive impairment, peptic ulcers, and optic nerve disease.

Semax has accumulated one of the strongest evidence bases of any nootropic peptide, with human clinical trials demonstrating clear neurological benefits alongside an extensive body of animal research. Its defining characteristic is potent, rapid Brain-Derived Neurotrophic Factor (BDNF) upregulation — the mechanism underlying most of its cognitive-enhancing and neuroprotective effects.

Unlike stimulants or synthetic nootropics that work through receptor flooding or monoamine reuptake inhibition, Semax works through endogenous neurotrophic pathways — supporting the brain's own growth, repair, and optimisation mechanisms. This produces cognitive function research outcomes that are neurologically sustainable rather than tolerance-building or dependency-forming.

"Semax significantly increased BDNF mRNA expression in the hippocampus and frontal cortex, demonstrating potent neurotrophic activity." — Dolotov et al., Journal of Neurochemistry (2006)

---

How It Works — Mechanism of Action

1. BDNF & NGF Upregulation — The Core Mechanism Brain-Derived Neurotrophic Factor (BDNF) is the brain's primary growth and maintenance molecule — it drives neuroplasticity, supports the survival of existing neurons, promotes the growth of new neurons and synapses, and consolidates long-term memory. Semax produces rapid, pronounced BDNF upregulation in the hippocampus (memory) and prefrontal cortex (executive function, working memory, decision-making) — regions most critical to cognitive performance.

Semax also upregulates Nerve Growth Factor (NGF), which supports cholinergic neuron function and is implicated in learning and memory consolidation.

2. Dopamine & Serotonin Modulation Semax modulates dopaminergic and serotonergic neurotransmission — increasing the sensitivity and efficiency of these systems rather than flooding them. This contributes to improved motivation, mood stability, mental drive, and focused attention without the tolerance or comedown associated with dopaminergic stimulants.

3. Melanocortin Receptor Activation As an ACTH analogue, Semax retains partial melanocortin receptor (MC4R) activity — the same receptor implicated in cognitive processing, attention, and memory. This contributes to its nootropic effects independently of BDNF upregulation.

4. Neuroprotection via Anti-Inflammatory & Anti-Apoptotic Pathways Semax has been shown to:

• Reduce neuroinflammation by downregulating pro-inflammatory cytokines in brain tissue
• Activate anti-apoptotic (cell death-prevention) signalling in neurons
• Improve cerebral blood flow and oxygen utilisation
• Protect against ischaemic (stroke-related) brain damage

These mechanisms underpin its clinical use in cerebrovascular conditions in Russia.

5. Enkephalinase Inhibition Semax inhibits the enzymes that break down endogenous enkephalins (endorphin-like neuropeptides), extending their anxiolytic and mood-stabilising effects — a mechanism shared with Selank.

"Intranasal Semax administration produced significant neuroprotective effects in experimental cerebral ischaemia models, reducing infarct volume and improving neurological outcomes." — Gusev et al., Cerebrovascular Diseases (1997)

---

Research-Backed Benefits

Cognitive Function & Memory Research

• Improved working memory, information processing speed, and learning rate
• Enhanced long-term memory consolidation via BDNF-driven hippocampal synaptic strengthening
• Improved executive function: planning, cognitive flexibility, and decision-making
• Rapid onset — effects on focus and mental clarity often noticeable within 30–60 minutes of intranasal administration

"Semax improved cognitive performance and attention in patients with cerebrovascular insufficiency in a double-blind randomised controlled trial." — Ashmarin et al., Neuroscience and Behavioural Physiology (1997)

Focus & Attention

• Sustained concentration without the stimulant-like hyperarousal or crash associated with caffeine or amphetamine-class compounds
• Reduced cognitive fatigue under prolonged mental effort
• Improved signal-to-noise ratio in cognitive processing — greater ability to filter distraction and maintain task focus

Neuroprotection & Brain Health

• Protection against ischaemic brain injury (stroke, TBI) — the original clinical indication
• Reduced neuroinflammation
• Potential support for age-related cognitive decline prevention
• Emerging research in Alzheimer's disease models showing amyloid-beta toxicity protection

Mood & Motivation

• Improved mood and motivation through dopaminergic and serotonergic modulation
• Reduced anxiety — complementary to Selank when combined
• Enhanced mental drive and goal-directed behaviour

Optic Nerve & Visual Processing

• Clinically approved in Russia for optic nerve atrophy and glaucoma-associated visual decline — demonstrating neurotrophic effects extend to peripheral nervous system tissue

---

Dosing & Administration

Primary Route: Intranasal Spray Intranasal delivery provides direct CNS access via the olfactory pathway, bypassing the blood-brain barrier. This route is strongly preferred for Semax — it provides high CNS bioavailability with a small systemic dose.

Standard Dose: 200–900 mcg per administration (typically 300–600 mcg is the research sweet spot) Frequency: Once or twice daily Cycle Length: 10–14 days on, 7–14 days off — cycling preserves sensitivity and prevents receptor downregulation

Available Variants:

• Standard Semax (0.1%): 100 mcg per spray — standard starting concentration
• Semax 1%: 1000 mcg per spray — used in higher-dose neuroprotective protocols
• N-Acetyl Semax (NA Semax): Acetylated form with greater lipophilicity and potentially enhanced CNS penetration; studied for enhanced CNS penetration and cognitive function research

Subcutaneous Injection (Less Common):

• Dose: 200–500 mcg once or twice daily
• Used when intranasal formulation is unavailable or when systemic neuroprotective effects are the primary goal
• Cycle: 10–20 days on, equal break off

Timing Best Practices:

• Morning dosing is strongly preferred — Semax can be activating and may interfere with sleep onset if taken in the evening
• Effects typically onset within 20–40 minutes of intranasal administration
• Cognitive and mood benefits tend to compound over 5–7 days of consistent use

Storage: Refrigerate at 2–8°C. Reconstituted injectable: use within 28 days. Nasal spray: follow manufacturer guidelines (typically 2–8°C).

---

Side Effects & Safety

Semax has an excellent safety profile supported by decades of Russian clinical use and extensive preclinical data. No significant adverse effects have been documented at therapeutic doses.

Commonly reported (mild and transient):

• Mild nasal irritation or dryness with intranasal use — typically resolves within the first few days
• Mild headache in some users, particularly initially — usually resolves within the first cycle
• Increased energy or mild activation — can interfere with sleep if dosed in the evening
• Rare reports of mild irritability — usually associated with higher doses

Key safety advantages:

• No addiction or dependency — no evidence of physical dependence
• No tolerance development with cycling protocol — efficacy is maintained
• No stimulant-like side effects — no cardiovascular elevation, jitteriness, or crash
• Reversible — all effects resolve after discontinuation

Important safety considerations:

• Bipolar disorder or psychosis — BDNF upregulation and dopaminergic modulation warrant psychiatric supervision in these populations; consult your physician
• MAO inhibitors or other psychiatric medications — potential interactions with serotonergic or dopaminergic medications; consult your physician
• Pregnancy and breastfeeding — avoid use; safety data not established
• Children — not appropriate for use in paediatric populations outside specialist clinical settings

---

Synergy Stacks

The Ultimate Nootropic Stack: Semax + Selank The most well-documented nootropic peptide combination in the Russian clinical literature. Semax drives BDNF, focus, memory, and cognitive performance; Selank provides emotional stability, anxiety reduction, and GABAergic balance. Together they address cognitive performance (Semax) and cognitive environment (Selank) — the full spectrum of mental optimisation.

"The combined use of Semax and Selank showed additive effects on cognitive performance and behavioural control." — Andreeva et al., Neuroscience and Behavioural Physiology

Neuroplasticity & Recovery: Semax + BPC-157 BPC-157's neurotrophic and neuroprotective properties complement Semax's BDNF upregulation — a stack with potential for recovery from traumatic brain injury, post-concussion syndrome, or cognitive impairment from chronic stress or illness.

Cognitive Ageing Research: Semax + NAD+ + Epitalon NAD+ provides cellular energy and sirtuin-driven gene expression support; Epitalon regulates the pineal and neuroendocrine systems; Semax drives BDNF-mediated neuroplasticity. A comprehensive brain health and cognitive ageing research protocol.

Sleep & Cognitive Recovery: Semax + CJC-1295 + Ipamorelin GH secretagogues improve sleep depth, slow-wave sleep quality, and overnight cellular repair — the biological foundation on which Semax's BDNF-driven learning and memory consolidation depends. Stack Semax in the morning; GH secretagogues in the evening.

Mood & Drive: Semax + Epitalon Epitalon's melatonin and circadian rhythm regulation combined with Semax's dopaminergic and serotonergic modulation — a comprehensive mood and wellbeing stack, particularly useful during periods of circadian disruption, travel, or chronic stress.